Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome
Table 2
Outcome parameters at baseline and after 6-month metformin treatment for patients with PCOS who were insulin sensitive at baseline (PCOS-C), patients with IR at baseline and after treatment (PCOS-PIR), and initially insulin resistant patients whose IR dissolved after treatment (PCOS-exIR).
PCOS-C*
PCOS-exIR*
PCOS-PIR*
Two-factorial ANOVA or Wilcoxon testa
Baseline
After treatment
Baseline
After treatment
Baseline
After treatment
HOMA-IR >2.5 [%]
0
5.6
100
0
100
100
HOMA-IR [mmol*mU/L²]
1.4 ± 0.7
1.1 ± 0.8
3.6 ± 0.9
1.5 ± 0.7***
6.2 ± 3.0
4.4 ± 1.8**
Time Group Time × Gr
Fasting insulin [µU/mL]
6.3 ± 3.1
5.3 ± 3.3
15.0 ± 3.4
7.0 ± 2.9***
25.9 ± 10.9
19.7 ± 7.5**
Time Group Time × Gr
AUCI [mU*h/L]
127 ± 48
132 ± 55
247 ± 109
169 ± 76***
347 ± 151
356 ± 142
Time Group Time × Gr
BMI [kg/m²]
26.8 ± 6.4
26.6 ± 6.4
31.9 ± 6.9
29.8 ± 6.3***
39.2 ± 8.4
38.5 ± 8.4
Time Group Time × Gr
Body weight [kg]
75.9 ± 21.1
75.2 ± 21.3
90.2 ± 21.7
84.4 ± 19.4***
110.6 ± 24.2
108.9 ± 24.0
Time Group Time × Gr
Cholesterol [mg/dL]
186 ± 28
196 ± 34
182 ± 32
186 ± 39
192 ± 34
190 ± 26
Time Group Time × Gr
LDL-cholesterol [mg/dL]
102 ± 22
105 ± 28
106 ± 26
103 ± 31
117 ± 32
113 ± 22
Time .1, Group Time × Gr
HDL-cholesterol [mg/dL]
63 ± 14
63 ± 15
49 ± 11
53 ± 13
48 ± 10
50 ± 11
Time Group Time × Gr
Triglycerides [mg/dL]
84 ± 48
101 ± 43
128 ± 70
122 ± 51
191 ± 217
153 ± 68
Time Group Time × Gr
AST [U/L]
25 ± 29
17 ± 5
20 ± 5
21 ± 6
21 ± 8
Time Group Time × Gr
ALT [U/L]
26 ± 14
28 ± 10
23 ± 9**
32 ± 13
Time , Group Time × Gr
AST/ALT-ratio
0.89 ± 0.3
0.86 ± 0.2
0.76 ± 0.2
0.86 ± 0.2
0.69 ± 0.2
0.61 ± 0.2
Time , Group Time × Gr
M30 [U/L]
198 ± 91
206 ± 124
199 ± 108
196 ± 70
238 ± 211
275 ± 206
Time Group Time × Gr ,
BARD-Score [median (25th, 75th percentile)]
2 (0.25, 2.75)
2 (1, 2.75)
1 (1, 3)
2 (1, 3)
1 (1, 2.5)
1 (1, 1)
Time
Data were analyzed with repeated measures analysis of variance with the factors group (i.e., PCOS-C, PCOS-IR, and PCOS-exIR) and time (i.e., changes from baseline to 6 months of treatment). In case of significant ANOVA time or time × group effects, post hoc paired -tests within respective PCOS groups were calculated (, and nonsignificant after Bonferroni correction). Changes in BARD-Scores from baseline to 6 months after treatment were analyzed with Wilcoxon tests within subgroups and the total sample. All results are shown as mean ± standard deviation, unless otherwise indicated.
